ALOPM Share Price Performance
€0.66
0.28 (72.47%)
Price €0.66
Share Pricen/a
Oncodesign Precision Medicine Société anonyme Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
ALOPM Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Oncodesign Precision Medicine Société anonyme Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- 0.35
- 535.56%
- 360.70%
- 62.8%
About ALOPM
- Founded
- 1995
- Employees
- 14
- CEO
- WebsiteView website
Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company’s product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson’s disease. It also focuses on the development of a radiotheranostic molecule portfolio for the diagnosis and the treatment of advanced digestive cancers, as well as on developing treatment for pancreatic and other cancers. Oncodesign Precision Medicine Société anonyme was founded in 1995 and is based in Dijon, France.
